VTT to work on cancer drug for Bayer

Collaboration agreement

VTT Technical Research Centre in Finland signed a two year contract with Bayer Schering Pharma AG to study the mode of action of a cancer drug developed by the German pharmaceutical company.

The work will use novel gene and cell biology methods developed by VTT. The contract furthers VTT's ambitions in expanding its competence in drug development. The organisation’s Medical Biotechnology unit has a programme that is identifying genes involved in prompting the formation of tumours, and another searching for drug compounds for preventing the growth and metastasis of breast and prostate cancer.